{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:13:42Z","timestamp":1791335622129,"version":"4.3.1"},"reference-count":18,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme United Kingdom","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","award":["MISP60977"],"award-info":[{"award-number":["MISP60977"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.cllc.2025.12.010","type":"journal-article","created":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T06:45:13Z","timestamp":1767249913000},"page":"75-79","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pembrolizumab Plus Platinum Doublet Chemotherapy With Lenvatinib in Unresectable Pleural Mesothelioma as First-Line Treatment (PENINSULA): A Study Protocol for a Single-Arm, Multi-Institutional, Phase II Clinical Trial"],"prefix":"10.1016","volume":"27","author":[{"given":"Tetsuya","family":"Takagawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanae","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Orimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukie","family":"Morisaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Suna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Daimon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8007-1516","authenticated-orcid":false,"given":"Kozo","family":"Kuribayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.cllc.2025.12.010_bib0001","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/ajim.20868","article-title":"Clinical study on mesothelioma in Japan: relevance to occupational asbestos exposure","volume":"53","author":"Kishimoto","year":"2010","journal-title":"Am J Ind Med"},{"key":"10.1016\/j.cllc.2025.12.010_bib0002","unstructured":"Statistics Department, Minister\u2019s Secretariat, Ministry of Health, Labour and Welfare. Patient survey 2014. Japan. Available at: https:\/\/www.e-stat.go.jp\/en\/stat-search\/files?page=1&toukei=00450022&tstat=000001031167. Accessed January 20, 2026."},{"issue":"3","key":"10.1016\/j.cllc.2025.12.010_bib0003","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2486\/indhealth.MS1184","article-title":"Future trends of mesothelioma mortality in Japan based on a risk function","volume":"50","author":"Myojin","year":"2012","journal-title":"Ind Health"},{"issue":"18","key":"10.1016\/j.cllc.2025.12.010_bib0004","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1158\/1078-0432.CCR-19-0103","article-title":"Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase II study in malignant pleural mesothelioma (MERIT)","volume":"25","author":"Okada","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2025.12.010_bib0005","doi-asserted-by":"crossref","unstructured":"Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375-86. doi:10.1016\/S0140-6736(20)32714-8.","DOI":"10.1016\/S0140-6736(20)32714-8"},{"issue":"8","key":"10.1016\/j.cllc.2025.12.010_bib0006","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1111\/cas.70082","article-title":"KEYNOTE-A17: first-line pembrolizumab plus cisplatin-pemetrexed in Japanese participants with advanced pleural mesothelioma","volume":"116","author":"Kijima","year":"2025","journal-title":"Cancer Sci"},{"issue":"10419","key":"10.1016\/j.cllc.2025.12.010_bib0007","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/S0140-6736(23)01613-6","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial","volume":"402","author":"Chu","year":"2023","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.cllc.2025.12.010_bib0008","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.annonc.2024.12.014","article-title":"A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trial","volume":"36","author":"Felip","year":"2025","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2025.12.010_bib0009","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1021\/ml500394m","article-title":"Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization","volume":"6","author":"Okamoto","year":"2015","journal-title":"ACS Med Chem Lett"},{"issue":"11","key":"10.1016\/j.cllc.2025.12.010_bib0010","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S1470-2045(23)00446-1","article-title":"Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study","volume":"24","author":"Douma","year":"2023","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.cllc.2025.12.010_bib0011","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/bjc.2013.374","article-title":"Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer","volume":"109","author":"Nishio","year":"2013","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.cllc.2025.12.010_bib0012","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.cllc.2025.12.010_bib0013","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.cllc.2025.12.010_bib0014","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.21873\/anticanres.17244","article-title":"True benefits of immune checkpoint inhibitors in the treatment of malignant pleural mesothelioma in Japan","volume":"44","author":"Kuribayashi","year":"2024","journal-title":"Anticancer Res"},{"issue":"20","key":"10.1016\/j.cllc.2025.12.010_bib0015","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1200\/JCO.2011.41.5869","article-title":"Gemcitabine\/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma: a randomized phase II trial","volume":"30","author":"Kindler","year":"2012","journal-title":"J Clin Oncol"},{"issue":"10026","key":"10.1016\/j.cllc.2025.12.010_bib0016","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"issue":"31","key":"10.1016\/j.cllc.2025.12.010_bib0017","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1200\/JCO.2017.72.9012","article-title":"Nintedanib plus pemetrexed and cisplatin in patients with malignant pleural mesothelioma: phase II results from the randomized, placebo-controlled LUME-Meso trial","volume":"35","author":"Grosso","year":"2017","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.cllc.2025.12.010_bib0018","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S2213-2600(19)30139-0","article-title":"Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"7","author":"Scagliotti","year":"2019","journal-title":"Lancet Respir Med"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730425003389?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730425003389?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T11:12:43Z","timestamp":1775041963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730425003389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1525730425003389"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2025.12.010","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pembrolizumab Plus Platinum Doublet Chemotherapy With Lenvatinib in Unresectable Pleural Mesothelioma as First-Line Treatment (PENINSULA): A Study Protocol for a Single-Arm, Multi-Institutional, Phase II Clinical Trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2025.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}